Physician profile
Senthil Krishnasamy
NPI 1548250202
$46,264.93
in general payments reported to CMS, 2019-2025
37 companies · $3,763 in 2025
The $3,763 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,429 · 2020: $1,419 · 2021: $2,214 · 2022: $29K · 2023: $2,575 · 2024: $3,374 · 2025: $3,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,712.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $25,923.89 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $3,056.12 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $2,918.28 | 2019-2025 | Hydrus Microstent, Clareon Panoptix Pro, Clareon |
| Bausch & Lomb Americas INC. | $1,620.21 | 2022-2025 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $1,456.29 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,265.10 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,240.73 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $1,181.43 | 2022-2025 | Lumera 700, Visumax, Artevo 800 |
| Glaukos Corporation | $1,003.70 | 2019-2025 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $700.48 | 2019-2023 | |
| Biotissue Holdings INC. | $647.00 | 2020-2024 | |
| Eyevance Pharmaceuticals LLC | $604.35 | 2021-2023 | Flarex |
| Allergan, INC. | $545.78 | 2019-2022 | |
| Ivantis, INC | $531.37 | 2019-2021 | |
| Sight Sciences, INC. | $497.94 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $462.87 | 2019-2020 | |
| Rxsight INC | $340.41 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $327.22 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $324.22 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $221.02 | 2019-2020 | |
| New World Medical,INC. | $204.67 | 2021-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Ocular Therapeutix, INC. | $180.76 | 2019-2023 | Dextenza |
| Beaver-Visitec International, INC. | $152.48 | 2019-2023 | |
| Oyster Point Pharma, INC. | $144.26 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $118.88 | 2025 | Acthar |
| Harrow Eye, LLC | $117.02 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $110.30 | 2022 | |
| Astellas Pharma US INC | $63.95 | 2023-2025 | Izervay |
| Leica Microsystems INC. | $61.00 | 2024 | Surgical Microscopes |
| The Cameron-Ehlen Group, INC. | $48.63 | 2020 | |
| Shire North American Group INC | $47.31 | 2019 | |
| Ani Pharmaceuticals, INC. | $44.12 | 2023 | Purified Cortrophin Gel |
| Santen INC. | $23.80 | 2023 | Verkazia |
| Amgen INC. | $23.54 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech USA, INC. | $18.52 | 2022 | |
| Horizon Therapeutics Plc | $17.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senthil Krishnasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.